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ĐŽŶŽŵŝĐĂŶĂůǇƐŝƐŽĨƚŚĞƉƌĞǀĂůĞŶĐĞĂŶĚ
ĐůŝŶŝĐĂůĂŶĚĞĐŽŶŽŵŝĐďƵƌĚĞŶŽĨŵĞĚŝĐĂƚŝŽŶ
ĞƌƌŽƌŝŶŶŐůĂŶĚ 
ABSTRACT 
 
Objectives 
To provide national estimates of the number and clinical and economic burden of medication errors in the 
National Health Service (NHS) in England. 
 
Methods 
We used United Kingdom-based prevalence of medication errors (in prescribing, dispensing, administration 
and monitoring) in primary care, secondary care and nursing home settings, and associated healthcare 
resource use, to estimate annual number and burden of errors to the NHS.  Burden (health care resource use 
and deaths) was estimated from harm associated with avoidable adverse drug events (ADEs).  
 
Results 
We estimated that 237 million medication errors occur at some point in the medication process in England 
annually, 71% occurring in primary care. 72% have little/no potential for harm and 66 million are potentially 
clinically significant. Prescribing in primary care accounts for 34% of all potentially clinically significant errors. 
Definitely avoidable ADEs are estimated to cost the NHS £98,462,582 per year, consuming 181,626 bed-days, 
causing/contributing to 1,708 deaths. This comprises primary care ADEs leading to a hospital admission 
(£83.7 million; causing 627 deaths), and secondary care ADEs leading to a longer hospital stay (£14.8 million; 
causing 85 deaths; contributing to 1,081 deaths).   
 
Conclusions 
Ubiquitous medicines use in health care leads unsurprisingly to high numbers of medication errors, although 
most are not clinically important. There is significant uncertainty around estimates due to the assumption 
that avoidable ADEs correspond to medication errors, data quality, and lack of data around longer-term 
impacts of errors. Data linkage between errors and patient outcomes is essential to progress understanding 
in this area. 
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INTRODUCTION 
 
Medication is the most widely used medical intervention. Harm caused by medication is referred to as an 
adverse drug event (ADE), and includes medication errors, adverse drug reactions, allergic reactions and 
overdoses.1 If an ADE is judged as being the result of an error, any resultant harm is regarded as 
preventable. The medicines use process includes prescribing, dispensing, administration and monitoring, 
involving different health care professionals and other key players in multiple geographical locations. If an 
error occurs at any one of these stages and reaches the patient, harm may occur. A medication error may be 
ĚĞĨŝŶĞĚĂƐ ? ?Any preventable event that may cause or lead to inappropriate medication use or patient harm 
while the medication is in the control of the health caƌĞƉƌŽĨĞƐƐŝŽŶĂů ?ƉĂƚŝĞŶƚ ?ŽƌĐŽŶƐƵŵĞƌ ?.2 Errors range 
from minor, with no harm, to major errors causing serious harm and death, and associated healthcare and 
wider costs. 
 
In 2007, the National Patient Safety Agency estimated that preventable harm from medication could cost 
over £750 million annually in England.3 Increasingly complex medical needs, and the introduction of many 
new medications, have resulted in ADEs being recognised as a key global issue. This has led to the World 
,ĞĂůƚŚKƌŐĂŶŝǌĂƚŝŽŶ ?Ɛ ?WHO) Third Global Patient Safety Challenge: Medication Without Harm.4 It aims to 
reduce the global level of severe, avoidable harm related to medications by 50% between 2017 and 2022. 
 
In response to this initiative, the Department of Health and Social Care (DHSC) in England commissioned us 
to estimate the prevalence and burden of medication error in the NHS. Up-to-date and robust estimates are 
needed to understand the scale of the problem and devise strategies to address it, and so our objectives 
were: (1) to estimate the number of medication errors nationally, by setting and by stage of the medication 
use process; (2) to estimate burden (defined as the costs to the NHS and health losses) due to medication 
errors.  
 
This paper provides a summary of the findings of our original report,5 with an updated literature review, 
some updates on burden estimates supported by more recently published data, and further exploration of 
the uncertainty around estimating numbers of errors and burden. 
METHODS 
 
Estimating the annual number of medication errors in the NHS in England  
 
We estimated the number of medication errors by combining published error prevalence estimates reported 
in a recent rapid systematic review of studies reporting medication error rates in the United Kingdom (UK).5 
The search strategy is summarised in the supplementary material. 
 
Prevalence of medication error 
 
Table 1 summarises evidence on medication error prevalence, by stage and setting, obtained from the 
review. Where more than one source had met our quality criteria (see Supplementary Appendix), the study 
with the patient population most generalisable to current UK practice was selected. Studies reporting 
secondary care administration errors were conducted in specific areas of medicine, so the arithmetic mean 
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was derived to estimate prevalence.6-10 Sensitivity analysis was conducted using alternative sources to 
inform the prevalence of prescribing errors in secondary care (10.9%)11 and administration errors in care 
homes (40.7%)12, see Supplementary Material for rationale. 
 
Table 1: Prevalence of medication errors in the NHS in England per opportunity for error*$ 
$Stage in the 
medication use 
process 
Setting 
Primary (ambulatory) 
care (%) 
Care homes (long-stay 
residential care 
including nursing 
homes) (%) 
Secondary (hospital) care 
(%) 
Prescribing 4.213 8.314 9.015 
Transition** No UK data available  No UK data available 20.816 
Dispensing 3.117 9.814 No UK data available  
Administration N/A*** 8.414 $$ 18.6$$$ 
Monitoring 1.7613 1.7414 No UK data available 
*Opportunities for prescribing and monitoring errors arise each time an item is prescribed, so the same 
medicine prescribed monthly, or 12 different medicines on the same prescription both represent 12 
opportunities for prescribing and monitoring errors. 
Opportunities for dispensing errors arise each time a prescribed medicine is dispensed. As with prescribed 
items, the same medicine dispensed monthly, or 12 different medicines dispensed from the same prescription 
both represent 12 opportunities for dispensing errors. 
Opportunities for administration errors arise every time a dose is administered or omitted in error, and so one 
medicine taken three times daily, or three medicines taken once daily, both represent three opportunities for 
error. 
Opportunities for transition errors arise each time a discharge prescription is issued, regardless of the number 
of items on it. 
**medicines prescribed and dispensed on discharge from hospital to primary care or care homes; 
***administration in primary care assumed to be patient-led and not under the control of health care 
professionalƐ ?ƚŚŝƐŝƐŐĞŶĞƌĂůůǇƌĞĨĞƌƌĞĚƚŽĂƐ “ĂĚŚĞƌĞŶĐĞ ? ?ŝŶƚŚŝƐƐƚƵĚǇǁĞĞǆĐůƵĚĞĚĂŶǇ “ĞƌƌŽƌƐ ?ƚŚĂƚŵŝŐŚƚ
arise from suboptimal adherence; 
$Data are all from England 
$$administered doses; 
$$$unweighted arithmetic mean derived from five UK studies set in specific patient populations, this includes 
both oral and parenteral administration6-10 
UK: United Kingdom 
 
Number of opportunities for error by stage and setting  
We calculated the number of opportunities for error by stage and setting for the whole of England in one 
year (see Table S1 and S2 (Supplementary Material)). 
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Primary care. We found no national data around annual number of items prescribed, hence we assumed 
that it is similar to the number of items dispensed; this is an underestimate as some items are prescribed but 
not necessarily dispensed. We obtained the number of items dispensed annually from NHS statistics in 2015-
16 (1,104 million items18) and deducted items dispensed for people residing in care homes. We assumed 
that monitoring errors only occur in repeat items (77% of total items dispensed).  
 
Care homes. We calculated the number of items used annually by care home residents by multiplying 
number of care home residents (416,00019) by average number of items used per day (7.2 items14), assuming 
monthly prescription and dispensing, and daily administration. Twice daily administration was explored in 
sensitivity analysis. 
 
Secondary care. We calculated number of items dispensed to inpatients from total hospital admissions in 
2015-16 (9,364,860 hospital admissions20) and the average number of items prescribed per inpatient 
(4.7815). We calculated items administered in hospitals annually by multiplying the number of beds available 
(131,072 in England21) by the average bed occupancy (87.23%21) and the average number of items 
prescribed per inpatient, assuming daily administration. Twice daily administration was explored in 
sensitivity analysis. 
 
Transition. We calculated the number of prescriptions issued at discharge using the number of total hospital 
discharges in 2015-16 (16,251,84120), and assumed one prescription per discharged patient. 
 
Calculating the annual number of medication errors  
We calculated the number of medication errors by multiplying error prevalence estimates by medication use 
estimates. Given the lack of data on dispensing and monitoring errors in secondary care, we generalised 
error prevalence from primary care.  
 
Estimating burden due to medication errors: severity, patient harm and costs  
 
Linking errors to burden requires information about which errors persist through the medication use 
process, and the impact on patients and healthcare utilisation. Studies identified through the rapid 
systematic review of recent UK-based studies found very little good quality data that linked harm to errors.5 
13 22 This is partly due to challenges in following up patients from error to harm, and attributing harm to 
errors. To deal with this evidence gap, studies have ranked errors by subjective judgment of potential of 
errors to cause harm, some using expert panel-derived cƌŝƚĞƌŝĂƚŽĚŝǀŝĚĞĞƌƌŽƌƐŝŶƚŽ “ŵŝŶŽƌ ? ? “ŵŽĚĞƌĂƚĞ ? ?Žƌ
 “ƐĞǀĞƌĞ ? ?23 This approach does not allow estimation of harm but can help to understand what errors could 
lead to the most severe harm. 
 
In the absence of data linking errors to harm, or systems to capture that data, the harm from errors can only 
be identified when someone experiencing harm presents to primary or secondary care. To quantify burden 
of errors, some studies link ADEs to patient harm and cost, and then assess retrospectively whether the ADE 
was preventable (that is, caused by a medication error). It is not always clear whether the ADE was caused 
by a medicine. Many studies have dealt with issues of causality and preventability, generally categorising 
errors by some subjective judgment.24-26  
 
Due to lack of data, we developed estimates of harm by: 
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1) Estimating proportion of errors likely to cause minor, moderate or severe harm in each setting and 
at each stage of the medication use process; 
2) Identifying published UK-based studies measuring the burden from ADEs and extrapolating to 
estimate the annual impact for England in terms of healthcare resource utilisation (and associated 
costs) and mortality.  
 
Estimating proportion of medication errors likely to cause minor, moderate or severe harm  
 
Five studies used to estimate error prevalence assessed the proportion of errors with potential to cause 
minor, moderate or severe harm7 13 15 17 27 (Table 2). The different methods used are discussed in the 
Supplementary Appendix. 
 
We calculated the number of medication errors that had potential to cause minor, moderate or severe harm 
by applying data from Table 2 to our estimate of medication errors. No UK data were available for care home 
errors. Therefore, we generalised the severity of errors in care homes from primary care for prescribing, 
dispensing and monitoring, and from secondary care for administration. We generalised the severity of 
transition errors in secondary care from the severity of prescribing errors in secondary care.   
 
Table 2: Potential of errors to cause harm from UK studies 
Error category 
Percentage of all errors by severity in each health care setting 
Primary care (%) Care homes Secondary care (%) 
Prescribing Mild: 49.4% 
Moderate: 49.8% 
Severe: 0.81%13 
No UK data available 
Mild: 41.1% 
Moderate: 51.6% 
Severe: 7.3%15 
Transition No UK data available  No UK data available No UK data available 
 
Dispensing Mild: 64.8% 
Moderate: 34.1% 
Severe: 1.1%17 
No UK data available 
 
Mild: 85.7% 
Moderate: 8.6% 
Severe: 5.7%27 
Administration 
N/A 
No UK data available 
 
Mild: 92.4% 
Moderate: 7.3% 
Severe: 0.3%7 
Monitoring Mild: 10.9% 
Moderate: 72.7% 
Severe: 16.4%13 
No UK data available 
 
Mild: 10.9% 
Moderate: 72.7% 
Severe: 16.4%15 
 
 
Quantifying burden (patient harm and NHS cost) of errors 
 
To estimate the burden of medication errors using published work it was necessary to rely upon 
retrospective judgements that the harm presented was firstly due to an ADE and secondly that it was 
avoidable. The primary approach was to identify published UK-based case studies measuring the burden 
from ADEs and estimate the annual impact for England in terms of healthcare resource utilisation (and 
associated costs) and mortality. Data from non-UK case studies were used to supplement this evidence in 
scenario analyses. The work reported here results from literature review to October 2018, updating the 
review carried out for the original DHSC report (October 2017). 
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Source studies were identified from the rapid review and expert consultation.24 28-31 Applying quality criteria 
used in the rapid reviews,32 we included studies judged as generally high quality, all but one29 using pre-
defined and published criteria to identify ADEs and all using published criteria to determine avoidability. We 
included two studies published more than ten years ago as more recent data were not available.24 30  
 
<ĞǇĂƐƐƵŵƉƚŝŽŶƐĂƌĞƚŚĂƚ “ĚĞĨŝŶŝƚĞůǇ ?ĂǀŽŝĚĂďůĞƐ ?ĂƐĐůĂƐƐŝĨŝĞĚďǇƚŚĞƐŽƵƌĐĞƐƚƵĚŝĞƐ ?ĂƉƉƌŽǆŝŵĂƚĞƚŽ
harm caused by medication errors and that hospitalisation due to ADEs were associated with errors 
occurring in primary care. In the source study, hospitalisation due to ADEs were associated with errors 
occurring in primary care30, definitely avoidable ADEs were defined as those due to a drug treatment 
procedure inconsistent with present day knowledge of good medical practice.25 For the base-case, we 
considered the number of hospitalisations and deaths associated with ADEs in primary care,24 30 and 
increased length of hospitalisations associated with ADEs in secondary care.31  
 
The base-case estimate for secondary care ADEs included only increased length of stay and death during the 
hospital admission when the ADE occurred. A recent UK study estimated harm from a secondary care ADE 
persisting in the 8 weeks following discharge, and was explored as a scenario analysis.33 
 
Due to the limitations of source data, the time horizon for the estimates of patient harm and costs is limited 
to the initial acute event or hospitalisation. Unit costs attached to healthcare utilisation and other data used 
in the estimation of total costs are summarised in Table S2 (see Supplementary Material). The population-
level data to which the error rates were applied were recorded by the NHS or Office for National Statistics 
(ONS) for the year 2015/16 and are reported in Supplementary Material, Table S2. The number of 
admissions and bed days were calculated for the different sources of errors and then multiplied by the 
relevant unit costs to generate cost estimates.  
 
The following sections describe the source studies and assumptions used to derive the parameters upon 
which estimates of the burden of ADEs were based. 
 
 
Burden of ADEs occurring in primary care  
 
Admissions to hospital   
A prospective English study of ADEs leading to hospital admission in two hospitals reported 5.2% of 18,820 
admissions over 6 months were due to an ADE.30 Causality was assessed.25 Most ADEs were either definitely 
(9%) or possibly (63%) avoidable. From this, we estimated the avoidable admissions rate to be 0.47% for 
definitely avoidable and 3.74% for definitely or possibly avoidable ADEs. In another UK study, 265 (6.5%) 
admissions were judged to be medication-related and 178 (67%) judged avoidable.24 Potentially (definitely 
or possibly) avoidable ADEs were associated with 3.0% of admissions. From these two studies, hospital 
admissions due to definitely or possibly avoidable drug-related morbidity was assumed to account for 
between 3.0% and 3.74% (midpoint 3.4%) of all adult non-obstetric, non-elective, admissions. This estimate 
was used in scenario analysis. 
 
To estimate number of hospital admissions due to primary care ADEs, the number of non-elective finished 
admission episodes (FAEs) excluding obstetrics and paediatrics (to mirror the admissions observed in the 
source study30) was used as the denominator and multiplied by the observed error rate.30  
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Length of hospital stay 
The median length of stay (LOS) of admissions due to avoidable ADEs was reported to be 8 days (IQR: 4-18 
days).30 The mean LOS was not reported, but can be derived from the total number of bed-days reported 
(17,452) and number of admissions (1,225), to be 14.25 days. However the source study was over 10 years 
old and there has been a downward trend in average LOS in the NHS, therefore the average LOS in 2015/16  
(5 days) was used in the base case estimate.20 The two values from the source study (8 and 14.25 days) were 
used in scenario analysis. 
 
Deaths associated with ADEs occurring in primary care 
The same prospective UK study was used to estimate number of deaths associated with ADEs.30 From 18,820 
admissions analysed, deaths were identified as being a direct result of an ADE, giving an index hospitalisation 
death rate of 0.15% due to ADEs. The proportion of admissions due to ADEs that were fatal was 2.3% 
(around half of which were due to fatal GI bleeds). We assumed that as 9% ADEs in the source study30 were 
definitely avoidable, the same proportion of ADE-related deaths were also avoidable. This meant that 0.21% 
admissions due to avoidable ADEs resulted in death. To estimate the number of deaths due to primary care 
ADEs, the number of non-elective FAEs excluding obstetrics and paediatrics (to mirror the admissions 
observed in the source study30) was used as the denominator and multiplied by this figure. There were no 
data available to estimate directly the number of deaths in which primary care ADEs were a contributing 
factor. Literature regarding secondary care ADEs reported that the proportion which contributed to death 
was 12.7 times higher than the proportion which caused death.31 A sensitivity analysis assuming that primary 
care ADEs contributed to death in 29.2% (i.e. 2.3% x 12.7) of admissions was conducted. 
 
Burden of ADEs occurring in secondary care  
 
Hospital length of stay 
An English study assessed ADEs occurring in admissions.31 Of 3695 patient episodes, 545 (14.7%, 95% CI 
13.6 ?15.9%) experienced one or more ADEs, 53.3% of which were definitely (6.4%) or possibly (46.9%) 
avoidable. ADEs increased LOS by 4 days for 26.8% of patients experiencing an ADE. These data were used to 
estimate the increased LOS and associated costs due to ADEs occurring in secondary care. The rate of 
inpatient admissions during which there was an ADE observed by Davies et al.31 was applied to the number 
of elective and non-elective FAEs, excluding paediatrics and obstetrics; day cases were excluded from the 
base case estimate. A scenario analysis was conducted in which day cases were included.  
 
Deaths associated with ADEs occurring in secondary care 
Davies et al reported that out of the 3695 patient episodes assessed, there were 14 deaths in which an ADE 
was a contributing factor, and one of which was as a direct result of the ADE.31 This gave an index  rate of 
0.38% of all ADE-related admissions in which the ADE was a contributing factor to death and 0.03% in which 
the ADE was the direct cause of death. Assuming that 6.4% of these ADE-related deaths were definitely 
avoidable and 53.3% were definitely or possibly avoidable,31 annual national estimates of avoidable deaths 
in which inpatient medication errors caused or contributed to were generated. The number of deaths in 
which an ADE was a contributing factor was used as the base case estimate because of the small number of 
deaths (one) caused directly by an ADE observed in the source study. No data were available around impact 
for other measures of patient health.  
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Scenario analysis: post-discharge resource use associated with ADEs occurring in secondary care 
Parkeh et al reported that 37.0% of over 65s who are discharged from a non-elective hospital admission 
experienced some medication-related harm in the following 8 weeks, 74.0% of which were related to a 
prescription issued in secondary care.33 The authors also reported that 4.6% of medication-related harm 
involved a medication error (3.4% medication error alone; 1.2% ADE plus medication error). Therefore 1.3% 
(i.e. 4.6% of 74.0% of 37.0%) of non-elective admissions were associated with a medication error. Of these 
medication errors, 74.4% required some type of healthcare resource use. This included GP consultations 
(71.7%), outpatient clinic attendances (2.7%), and out-of-hours visits (1.8%). These estimates were applied 
to the number of non-elective admissions, excluding obstetrics and paediatrics, in 2015/16.  
 
Scenario analyses 
 
The base-case analysis included UK data only, necessarily excluding potential other impacts of errors, 
providing conservative estimates of burden. We carried out four scenario analyses around the burden of 
ADEs where we utilised data from other settings and economic modelling: 
 
x Burden from errors occurring in primary care: Admissions to intensive care, Accident and emergency 
visits not resulting in a hospitalisation, Primary health care contact not resulting in an A&E visit or 
hospitalisation  
x Burden from errors occurring in secondary care: Post-discharge resource use  
 
The methods, data sources and assumptions are detailed in the Supplementary Appendix. 
RESULTS 
 
Number of errors 
 
Number of opportunities for error by stage and setting in the NHS in England  
 
Table S2 (Supplementary Appendix) summarises the estimated number of opportunities for error by stage 
and setting for the whole of England in one year. 
 
 
Estimating the annual number of medication errors in the NHS in England  
 
A summary of the estimated annual number of errors in England is presented in Figure 1, with a detailed 
breakdown by severity in Table 3. 
 
<<Figure 1 here>> 
 
We have estimated that there are 237,287,788 medication errors in England in one year.  Errors occur at all 
stages of the medicines use process: prescribing (21.3%), transition (1.4%), dispensing (15.9%), 
administration (54.4%) and monitoring (7.0%), and in all settings: primary care (38.4%), care homes (41.7%), 
and secondary care (19.9%). Error rates per patient in primary care are the lowest, but the burden of errors 
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is the second highest due to the size of the sector. Care homes cover fewer patients than the other sectors, 
but have the highest error rates per patient, leading to a disproportionately high overall number of errors. 
 
 
Estimating burden due to medication errors  
 
Estimating proportion of medication errors likely to cause minor, moderate or severe harm  
 
The estimated numbers of errors per annum in England that could potentially lead to mild, moderate or 
severe harm are presented in Table 3. 
 
Table 3: Estimated number of errors per annum in England overall and for each stage of the medication use 
process in each setting, presented according to potential to cause harm 
Error category 
Number of medication errors per annum in England 
Primary care Care homes Secondary care Total for all 
settings 
Prescribing 
Minor   21,170,690  1,447,770  1,663,208  24,281,668  
Moderate  21,723,443  1,485,571  2,087,199  25,296,213  
Severe  729,367 49,878    293,338   1,072,583  
Total  43,623,500  2,983,219 4,043,745 50,650,464  
Transitioning 
Minor  No data No data 1,390,365 1,390,365 
Moderate No data No data 1,744,801 1,744,801 
Severe No data No data 245,217 245,217 
Total No data No data 3,380,383  3,380,383 
Dispensing 
Minor   21,295,902  2,281,526  891,667   24,469,095  
Moderate  11,208,369  1,200,803  469,298   12,878,470  
Severe  373,612  40,027  15,643   429,282  
Total  32,877,883  3,522,355 1,376,609 37,776,847  
Administration 
Minor  N/A 84,856,111 34,327,365 119,183,476 
Moderate N/A 6,727,552 2,721,538 9,449,090 
Severe N/A 249,169 100,798 349,967 
Total N/A 91,832,832 37,149,701 128,982,533 
Monitoring 
Minor   1,582,202  68,225  149,307 1,799,734 
Moderate  10,548,013  454,835   995,378 11,998,226  
Severe   2,373,303  102,338  223,960 2,699,601  
Total  14,503,519  625,398   1,368,644 16,497,561  
All medication use errors 
Minor  44,048,794  88,653,632  38,421,912  171,124,338  
Moderate 43,479,825  9,868,761  8,018,214  61,366,800  
Severe  3,476,282  441,412  878,956  4,796,650  
TOTAL 91,004,902  98,963,804  47,319,082  237,287,788  
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Of the 237.3 million medication errors in England annually, 72.1% are estimated to have the potential to 
cause minor harm only. Those errors with potential to cause moderate or severe harm, constitute 25.8% and 
2.0% of overall errors, respectively.  
 
Sensitivity analysis explored alternative sources of the prevalence of error, and assumptions regarding 
number of daily doses of each administered medicine. Alternative scenarios led to a higher number of 
overall errors (238,118,974 - 590,406,892), but relatively similar number of errors that could be associated 
with moderate or severe harm (66,610,373  ? 92,990,602, compared with 66,163,450 in the baseline 
scenario). 
 
Quantifying burden (patient harm and NHS cost) of errors 
 
The base case uses only UK-based data on hospitalisations linked to definitely avoidable ADEs occurring in 
primary care leading to hospital admission and definitely avoidable ADEs during overnight hospital 
admissions. The estimated costs to the NHS are £98,462,582 annually, consuming 181,626 bed-days, causing 
712 deaths, contributing to 1,708 deaths during the index hospitalisation (Table 4). Two alternative scenario 
analyses were also estimated. Including both definitely and probably avoidable ADEs cost £728,462,837. 
Including inpatient ADEs during day case and overnight hospital admissions cost £111,844,008.  
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Table 4: Estimated national burden associated with primary and secondary care errors (base case scenario 
and alternative scenarios) 
Base case and higher cost scenarios Cost (£) Bed 
days/year 
Deaths 
Base case (hospitalisations linked to definitely avoidable primary care ADEs and definitely 
avoidable ADEs during overnight hospital admissions) 
Primary care ADEs30 
x 5.2% of hospitalisations due to primary care 
ADEs  
x 2.3% of ADE admissions directly result in death 
caused by the ADE 
x 29.2% of ADE admissions result in death for 
which an ADE was a contributing factor* 
x 9% of ADEs definitely avoidable 
x Length of stay 5 days 
83,673,627 136,811 627 
 
 
 
 
7958* 
Secondary care ADEs31 
x ADEs during overnight inpatient admissions  
(14.7% error rate); 4 days added to length of 
stay for 26.8% of patients with an inpatient 
ADE; £330 for each day added to admission;  
x 0.38% of all admissions result in a death for 
which an ADE was a contributing factor  
x 0.03% of all admissions result in a death 
caused by an ADE*  
x 6.4% of ADEs definitely avoidable 
14,788,955 44,815 1,081 
 
 
 
 
85* 
Total (base case) 98,462,582 181,626 1,708* 
Alternative scenarios 
Scenario 1a: (base case + probably avoidable ADEs) 
Primary care ADEs30 
x 5.2% of hospitalisations due to primary care 
ADEs  
x 2.3% ADEs directly resulting in death  
x 72% of ADEs probably or definitely avoidable 
605,298,575 989,697 5,013 
Secondary care ADEs31 
x ADEs during overnight inpatient admissions   
x Deaths for which inpatient ADE was a 
contributing factor  
x 53.3% of ADEs probably or definitely avoidable 
123,164,262 373,225 9,000 
Total (Scenario 1a) 728,462,837 1,362,922 14,013 
Scenario 1b: (base case + definitely avoidable ADEs during day case admissions) 
Primary care ADEs30 
x Hospitalisations due to primary care ADEs  
x 2.3% of ADEs directly result in death  
x 9% of ADEs definitely avoidable 
83,673,627 136,811 627 
Secondary care ADEs31 
x ADEs during all inpatient admissions   
x Deaths for which inpatient ADE was a 
contributing factor  
x 6.4% of ADEs definitely avoidable 
28,170,381 85,365 2,058 
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Base case and higher cost scenarios Cost (£) Bed 
days/year 
Deaths 
Total (Scenario 1b) 111,844,008 222,176 2,685 
*The base case estimate includes deaths in which a primary care ADE caused death and where a secondary 
care ADE was a contributing factor in death as these were the most robust estimates.  
ADE: adverse drug event 
 
Scenario analyses including the burden on other NHS services associated with medication errors are 
reported in Table 5. A full record of scenarios estimating the burden of errors under alternative assumptions 
is reported in Supplementary Material (Table S4). The highest cost scenario which includes possibly (and 
definitely) avoidable ADEs, assumes a 14.25 day admission for primary care errors, and includes the burden 
on the broader range of NHS services, estimates that errors cost the NHS £1,605,794,614 annually,  
3,817,817 bed-days, contributing to 22,303 deaths. 
 
 
Table 5: Scenario analyses: estimated burden including other NHS services associated with primary and 
secondary care errors  
Burden on other NHS services Cost (£) Bed 
days/year 
Deaths 
Base case (hospitalisations associated with definitely avoidable primary care errors and definitely 
avoidable errors during overnight hospital admissions) 
Total (base case) 98,462,582 181,626 1,708 
Primary care contacts associated with primary care errors34 
x 6.0% of primary care errors result in a visit to a GP 8,604,378* - - 
x 15.41% of primary care errors result in a visit to a 
GP 
22,098,911** 
 
- - 
A&E attendances associated with primary care errors 
x 16.2% of A&E attendances due to ADEs28 
x 20.5% are avoidable28 
x 79.8% of A&E attendances do not result in 
admission35 
75,902,982 - - 
ICU admissions associated with errors29 
x ICU admissions related to avoidable ADEs (8.1% of 
ICU admissions); length of ICU stay 4 days;  
x Death during ICU admission (14.0% of ICU 
admissions for avoidable ADEs)  
5,473,747 4,188 147 
Post-discharge resource use associated with 
secondary care errors33*** 
   
x GP visits (71.7% of errors requiring treatment) 
x Outpatient clinic visits (2.7% of errors requiring 
treatment) 
x Out-of-hours visits (1.8% of errors requiring 
treatment) 
1,702,245 - - 
*Based on 239,011 GP visits; **Based on 613,859 GP visits; ***Based on 5,821,746 non-elective admissions 
leading to 75,683 medication errors, 56,308 of which required treatment 
ADE = adverse drug event; A&E = accident and emergency; ICU = intensive care unit; GP = general 
practitioner; NHS = National Health Service 
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DISCUSSION 
 
Key findings 
 
We estimated that 237 million medication errors occur in England annually, costing the NHS £98,462,582, 
consuming 181,626 bed-days, and causing or contributing to 712 or 1,708 deaths, respectively.  
 
The estimated number of errors is the sum of medication errors over all stages of the medication use 
process. Most errors occur in administration (54%), prescribing (21%) and dispensing (16%). Most 
medication errors (72%) have little/no potential for harm, only 2% have potential to cause severe harm.  
 
Study limitations and assumptions 
 
Limitations stem mainly from lack of data. Source studies were generally conducted in small numbers of 
English centres. Our assumption that these data are generalisable to the whole NHS is a source of 
uncertainty. Estimates of the total number of errors represent the sum total of errors at each stage rather 
than the errors that actually reach patients.  
 
This study only considers medication errors under the responsibility of health care professionals and care 
staff, without including errors in administration and monitoring by patients and their caregivers. 
Additionally, some assumptions had to be made to calculate the number of medications prescribed and 
dispensed given the lack of data. We had to assume that the number of items prescribed in primary care 
equated to the number dispensed, which will have led to an underestimate of prescribed items, and any 
estimates of associated errors.  
 
Due to the lack of available data, we were not able to make direct links between errors and harm, or what 
proportion of errors occurring at different stages of the medicines use process reached patients, and what 
proportion of those errors reaching patients caused actual harm. Therefore, the estimates of error 
prevalence are generated from completely separate data from the data used to generate estimates of harm. 
We have had to assume that the errors we have estimated to occur will lead to the burden that we have 
estimated will occur. Studies included did not use comparable methods to assess severity of potential harm. 
 
 
A major, necessary, assumption in the estimation of the burden was that definitely avoidable ADEs 
constitute harm from errors. Estimated burden only included short-term costs and patient outcomes, we 
had no data on burden of errors managed in care homes, therefore it is likely to be an underestimate. Some 
key source studies from which the burden of errors was estimated were at least 10 years old, or from non-
UK countries in scenario analyses.  
 
Comparison with published estimates of medication error prevalence and burden 
 
Similarly to another recent review in this area, reported error rates differ widely between studies due to 
differences in methods.22 Error rates in the UK are similar to those in other comparable health settings such 
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as the US and other countries in the European Union for primary care prescribing,36 secondary care 
prescribing,37 dispensing,38 and administration.39  
 
Implications for policymakers 
 
This work helped inform recent policy initiatives that aim to monitor and reduce medication errors. 
Specifically, it informed the DHSC decision to commission a new system to monitor and prevent medication 
errors and the development of indicators for safer prescribing, by linking prescribing data in primary care to 
hospital admissions.40 NHS Digital and NHS Business Services Authority were tasked to develop metrics to 
assess and monitor higher risk prescribing, and link this with outcomes such as hospital admission.  
 
Understanding the prevalence and burden of medication errors can help inform decisions about where to 
prioritise funding of patient safety initiatives to reduce the burden from medication errors. In parallel to our 
work, a short-life working group advised the English DHSC on what should be done to reduce medication 
errors.41  One key recommendation was that in primary care settings, the use of evidence-based 
interventions such as a pharmacist-led information technology intervention (PINCER)42 should be employed. 
Our work supports this recommendation, that primary care is a key setting for intervention, given our 
estimate that 71.0% (of 66 million clinically significant errors) occur in primary care and that prescribing in 
primary care accounts for 33.9% of all potentially clinically significant errors. The drugs most commonly 
implicated in hospital admissions due to ADEs are NSAIDs, antiplatelets, antiepileptics, hypoglycaemics, 
diuretics, inhaled corticosteroids, cardiac glycosides, and beta-blockers.24 Non-steroidal anti-inflammatory 
drugs (NSAIDs), anticoagulants and antiplatelets cause over a third of admissions due to avoidable ADEs.30 
Close to 80% of deaths were due to gastrointestinal bleeds caused by NSAIDs, aspirin, or warfarin.30 Older 
people are more likely to suffer avoidable ADEs.33 This presents a clear message for policymakers for where 
targeted interventions could have the greatest impact.  
 
Conclusions 
 
Ubiquitous medicines use in health care leads unsurprisingly to high numbers of medication errors, although 
most are not clinically important. There is significant uncertainty around estimates due to the assumption 
that avoidable ADEs correspond to medication errors, data quality, and lack of data around longer-term 
impacts of errors, although estimates suggest significant effects on patient health and healthcare. Effective 
targeting of finite healthcare resources to reduce medication errors requires understanding of where errors 
cause the most burden. Data linkage between errors and patient outcomes is essential to progress 
understanding in this area. 
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